Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy

被引：0
|
作者：
Huizing, D. [1 ]
Aalbersberg, E. A. [1 ]
Versleijen, M. W. J. [1 ]
Tesselaar, M. E. T. [1 ]
Walraven, I. [1 ]
Lahaye, M. J. [1 ]
de Wit-van der Veen, B. J. [1 ]
Stokkel, M. P. M. [1 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-276
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [31] Postoperative Complications after Previous Peptide-Receptor Radionuclide Therapy
    Kaemmerer, D.
    Prasad, V
    Baum, R. P.
    Hommann, M.
    NEUROENDOCRINOLOGY, 2012, 96 : 6 - 6
  • [32] Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy
    Piccin, Andrea
    Grana, Chiara Maria
    Negri, Giovanni
    Pusceddu, Irene
    Paganelli, Giovanni
    Cortelazzo, Sergio
    ANNALS OF HEMATOLOGY, 2012, 91 (02) : 299 - 300
  • [33] Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy
    Andrea Piccin
    Chiara Maria Grana
    Giovanni Negri
    Irene Pusceddu
    Giovanni Paganelli
    Sergio Cortelazzo
    Annals of Hematology, 2012, 91 : 299 - 300
  • [34] Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms
    Kaemmerer, Daniel
    Twrznik, Matthias
    Kulkarni, Harshad R.
    Horsch, Dieter
    Sehner, Susanne
    Baum, Richard P.
    Hommann, Merten
    ANNALS OF SURGERY, 2021, 274 (01) : E45 - E53
  • [35] Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
    Valkema, R
    Pauwels, S
    Kvols, LK
    Barone, R
    Jamar, F
    Bakker, WH
    Kwekkeboom, DJ
    Bouterfa, H
    Krenning, EP
    SEMINARS IN NUCLEAR MEDICINE, 2006, 36 (02) : 147 - 156
  • [36] Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
    Constantin Lapa
    Rudolf A Werner
    Christina Bluemel
    Katharina Lueckerath
    Dirk O Muegge
    Alexander Strate
    Heribert Haenscheid
    Andreas Schirbel
    Martin S Allen-Auerbach
    Ralph A Bundschuh
    Andreas K Buck
    Ken Herrmann
    EJNMMI Research, 4 (1)
  • [37] Predictors of survival in patients with neuroendocrine tumors after first full treatment cycle with peptide receptor radionuclide therapy
    Rodrigues, M.
    Nilica, B.
    Buxbaum, S.
    Uprimny, C.
    Gamper, E.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S212 - S212
  • [38] Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors
    Luis C. Borbon
    Scott K. Sherman
    Patrick J. Breheny
    Chandrikha Chandrasekharan
    Yusuf Menda
    David Bushnell
    Andrew M. Bellizzi
    P. H. Ear
    M. Sue O’Dorisio
    Thomas M. O’Dorisio
    Joseph S. Dillon
    James R. Howe
    Annals of Surgical Oncology, 2025, 32 (2) : 1136 - 1148
  • [39] The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours
    Ladwa, R.
    Pattison, D.
    Smith, J.
    Goodman, S.
    Burge, M.
    Rose, S.
    Dowson, N.
    Wyld, D. K.
    ANNALS OF ONCOLOGY, 2019, 30 : 570 - 570
  • [40] Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
    Lapa, Constantin
    Werner, Rudolf A.
    Bluemel, Christina
    Lueckerath, Katharina
    Muegge, Dirk O.
    Strate, Alexander
    Haenscheid, Heribert
    Schirbel, Andreas
    Allen-Auerbach, Martin S.
    Bundschuh, Ralph A.
    Buck, Andreas K.
    Herrmann, Ken
    EJNMMI RESEARCH, 2014, 4
12345